COVID-19 Still Dampens Neurocrine Revenues Despite Industry’s Q3 Uptick

A Pair Of Clinical Holds Hinders The Pipeline

The pandemic has hit psychiatry offices hard, and the company’s management said it anticipates flat sequential revenues in Q4.

More from Earnings

More from Business